Stryker Corporation

New York Stock Exchange
Back to all articles
Bearish -50

Stryker cyberattack ‘meaningfully’ impacted Q1

📉 CEO Kevin Lobo stated that the March cyberattack had a "big impact" on Stryker's first-quarter results and distorted revenue figures.

💻 The security breach, attributed to an Iran-linked group called Handala, shut down global Microsoft environments for weeks in late March.

🏭 Manufacturing, shipping, and ordering systems were disrupted until operations resumed in the first week of April.

💰 Reported Q1 sales totaled $6 billion, reflecting a 2.6% year-over-year growth rate, significantly lower than the typical 10-12% seen last year.

📊 RBC Capital Markets analyst Shagun Singh noted that organic sales missed consensus estimates by approximately $317 million due to the incident.

🎯 Despite the Q1 disruption, Stryker maintained its full-year guidance for organic sales growth between 8% and 9.5%.

💵 Full-year adjusted earnings per share guidance remains in the range of $14.90 to $15.10 despite first-quarter headwinds.

🔒 CEO Lobo clarified that while internal procedures were lost, the company did not lose overall customers or long-term business relationships.

📞 CFO Preston Wells expressed confidence that recovery in Q2 will help normalize results and meet full-year targets.

🧪 The cyberattack wiped thousands of servers and mobile devices but Stryker stated it maintained access to its core customer data.

🏥 Sales representatives faced challenges accessing hospital networks during the shutdown, impacting some procedural bookings.

📈 Stifel analyst Rick Wise maintained that healthy end-market trends support Stryker's long-term prospects for a strong growth year.

📉 J.P. Morgan analyst Robbie Marcus described Stryker as one of the highest quality and fastest-growing companies in MedTech despite the print.

🕒 The company expects to see recovery throughout the rest of 2026 following the operational disruption experienced in Q1.

💼 CEO Lobo emphasized that the company has come out of the incident "very strong" with no lasting loss of business.

Bullish Signals
  • Despite a 'meaningful' impact from the cyberattack, Stryker maintained its full-year guidance for organic sales growth in the range of 8% to 9.5% and adjusted earnings per share between $14.90 and $15.10.
  • CEO Kevin Lobo expressed confidence that any business lost during the first quarter would be recovered, stating, 'We've come out of this very strong,' with executives anticipating recovery in Q2 and beyond to meet full-year targets.
  • Analysts remain bullish on Stryker's long-term prospects; Stifel analyst Rick Wise noted healthy end-market trends and expected rest-of-2026 business recovery suggest the company is poised for a strong growth year ahead.
  • J.P. Morgan analyst Robbie Marcus highlighted that Stryker remains one of the highest quality, consistently fastest growing companies in MedTech, with investors expected to gravitate towards the stock now that the cyber incident impact has passed.
Risk Factors
  • CEO Kevin Lobo admitted the cyberattack 'meaningfully' impacted first-quarter results, causing a significant miss against consensus estimates of approximately $317 million per RBC Capital Markets analyst Shagun Singh.
  • Stryker reported first-quarter sales growth of only 2.6%, which is drastically lower than the company's typical 10% to 12% annualized growth rate seen in every quarter of the prior year.
  • The cyberattack on March 11 shut down ordering, shipping, and manufacturing operations for weeks, forcing Stryker to wipe 40,000 laptops and disrupt its global Microsoft environment until the first week of April.
  • The Iran-linked threat actor Handala claimed responsibility for wiping thousands of servers and mobile devices and stealing data, introducing long-term security risks even after operations were restored.
  • While Stryker maintained full-year guidance, the company explicitly noted that current financial results are 'distorted' by the attack and will not normalize until the rest of the year, creating near-term earnings volatility.
Full Analysis
MedSurg and Neurotechnology: $3.21 billion (ticker SYK) CEO Kevin Lobo confirmed that a significant cyberattack in mid-March 'meaningfully' impacted Stryker's first-quarter 2023 financial results, though the company maintained its full-year guidance for organic sales growth between 8% and 9.5% and adjusted earnings per share of $14.90 to $15.10. The attack, initiated on March 11 by an Iran-linked threat actor known as Handala, disrupted Stryker's Microsoft environment, forcing a shutdown of ordering, shipping, and manufacturing operations for several weeks until the first week of April. Consequently, Q1 net sales reached $6 billion with only 2.6% year-over-year growth, a notable dip compared to the 10% to nearly 12% growth seen in every quarter of the previous year. RBC Capital Markets analyst Shagun Singh noted that the company missed consensus estimates for organic sales by approximately $317 million due to these disruptions. Despite the operational setbacks, including the wiping of thousands of servers and mobile devices and the loss of 40,000 laptops, Stryker emphasized that it did not lose overall business, with CEO Kevin Lobo stating, "There isn't really any business I could think of that we've lost." The executive team expects a recovery trajectory in Q2 followed by continued growth in the remainder of the year to normalize the first-quarter results. Analysts from Stifel and J.P. Morgan remained confident in Stryker's long-term prospects, citing healthy end-market trends and consistent industry growth as reasons investors should gravitate toward the company now that the immediate cyber incident is behind them.